Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- PL Intelligence
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- PL Intelligence
- Overview
- Industry news
- Deals review
- Press releases
- Articles
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing
is a division of
is a division of
News of the day
CombiMatrix Publishes Clinical Study of Its HerScan(tm) Breast Cancer Test
MUKILTEO, Wash., Jun 3, 2009 -- CombiMatrix Corporation (Nasdaq:CBMX) today announced that the validation study performed by its wholly owned subsidiary, Combimatrix Molecular Diagnostics (CMDX), in collaboration with the Department of Pathology at the University of Texas Health Science Center in San Antonio, TX (UTHSCSA) is available as an advance online publication in the official journal of the United States and Canadian Academy of Pathology (USCAP), Modern Pathology. moreNovasep acquires bioprocess development specialist and contract manufacturer Henogen
Pompey, France, July 2, 2009 - Novasep, a leading producer of active pharmaceutical ingredients (APIs) and purification technologies for the life science industries, announces today the acquisition of Henogen, a contract manufacturing organization (CMO) offering bioprocess development and manufacturing services from the cell bank to the supply of clinical products. The move adds a complementary, market-leading range of upstream processing capabilities and services to Novasep's comprehensive... moreOpen Briefing
July 02, 2009-- Bionomics Limited (ASX: BNO) today announced it had identified a safe dosage for Phase II clinical trials of BNC105, its novel vascular disrupting agent (VDA) for the treatment of solid tumour types, and that it has contracted Hoosier Oncology Group Inc. ("HOG") to conduct a Phase II trial to evaluate the efficacy of BNC105 in renal cell carcinoma. Bionomics also recently initiated a Phase I clinical trial for BNC210, its potential blockbuster antianxiety drug. To what extent... moreIndustry news search
Most Viewed News
- EpiCept Partners With IDIS For Ceplene(R) Named Patient/Compassionate Use Program
- AVI BioPharma Signs an Additional Drug Development Contract with Charley's Fund Inc. for Duchenne Muscular Dystrophy
- First Phase III Clinical Trial results of Safinamide in Advanced Parkinson's disease at the Movement Disorder Society's 13th International Congress: Presentation and Conference Call
- Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
- Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 'CONNECTION' Trial of Dimebon in Patients With Alzheimer's Disease
- RSS Feed...
Latest news by therapeutic target
Cardiovascular
- NMT Medical, Inc (NMTI) Secures $4.0 Million Credit Agreement
- Overview Overview Antifolates Antifolates I-3D I-3D Droxidopa Droxidopa Strategy Strategy Dainippon Sumitomo Dainippon Sumitomo Active Biotech AB Active Biotech AB Strategy Strategy FAQ FAQ Analyst Coverage Analyst Coverage SEC Filings SEC Filings Stock Quote Stock Quote Fundamentals Fundamentals Info Request Info Request Email Alerts Email Alerts Corporate Governance Corporate Governance News News Events Events FAQ News SEC Filings Analyst Coverage Stock Quote Fundamentals Info Request Email Alerts Corporate Governance Press Releases Receive news via e-mail Chelsea Therapeutics Achieves Target Enrollment in Phase III Trial of Droxidopa in Neurogenic Orthostatic Hypotension
- Neovasc Inc. Postpones Plans for U.S. Listing to Focus Funds on Commercializing Its Reducer Device for Refractory Angina
- More news...
Dermatology
- PROVECTUS PHARMACEUTICALS COMPLETES PATIENT ACCRUAL IN INITIAL PHASE 2 STUDY OF PH-10 FOR ATOPIC DERMATITIS
- Dermatologic and Ophthalmic Drugs Advisory Committee Unanimously Recommends Bepreve(TM) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
- Dabur India Completes Acquisition Of Fem Care Pharma
- More news...
Endocrine and Metabolic
- Medical House supplies Merck Serono with new needle-free system for commercial launch
- Takeda Receives FDA Complete Response Letter for Alogliptin, An Investigational Treatment for Type 2 Diabetes
- Santhera Enters Agreement with Columbia University to Investigate Additional Potential of Catena
- More news...
Gastroenterology
- AspenBio Pharma Files 510(k) Notification With FDA for AppyScore(TM) Test
- Rexahn Pharmaceuticals Signs Development and Commercialization Agreement with a Top 20 Pharmaceutical Company for Novel Anti-cancer Compound
- Prometheus Launches MyCeliacID(TM), The First Do It Yourself, Saliva-Based Genetic Test Dedicated To Celiac Disease
- More news...
Infection
- Sinovac Receives Revised Approvals for Panflu
- SPANISH GOVERNMENT SELECTS NOVAVAX'S VLP TECHNOLOGY FOR COMPREHENSIVE FLU VACCINE SOLUTION IN SPAIN
- Inovio Biomedical, National Microbiology Laboratory, and University of Pennsylvania to Evaluate Candidate DNA Vaccines against "Swine" Influenza A (H1N1)
- More news...
Musculoskeletal
- HUMAN GENOME SCIENCES TO HOST JULY 20 CONFERENCE CALL TO DISCUSS TOP-LINE PHASE 3 RESULTS FOR BENLYSTA(TM) (FORMERLY LYMPHOSTAT-B
- POZEN Submits New Drug Application For VIMOVO(TM) (PN 400)
- Marketing Authorization Granted by KFDA for TMX-67, Chronic Management of Hyperuricemia in Patients with Gout
- More news...
Neurology
- Biogen Idec and Acorda Therapeutics Announce Collaboration Agreement to Develop and Commercialize MS Therapy Fampridine-SR in Markets Outside the U.S.
- Santhera's FJORD Phase IIb Study Demonstrates Efficacy of JP-1730/Fipamezole for the Treatment of Dyskinesia in Parkinson's Disease
- CytRx Files Report with the FDA in Response to the Partial Clinical Hold on its Phase 2b Arimoclomol ALS Trial
- More news...
Ophthalmology
- AGTC and National Neurovision Research Institute Collaborate, Funding Research in two Genetic Retinal Diseases
- Bausch & Lomb Kicks Off U.S. Consumer Online Marketing Campaign for SofLens
- Dermatologic and Ophthalmic Drugs Advisory Committee Unanimously Recommends Bepreve(TM) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
- More news...
Latest news by category
Financings
- Status regarding Novo Nordisk's holding of its own shares
- LabCorp Redeems All Outstanding Liquid Yield Option(TM) Notes Due 2021 and $369.1 Million Principal Amount at Maturity of Zero Coupon Convertible Subordinated Notes Due 2021
- Medidata Solutions Announces Exercise of Over-Allotment Option and Closing of Initial Public Offering
- More news...
Press releases
- Abdi Ibrahim , APR and Labtec GmbH have entered into an exclusive licensing agreement under which Abdi Ibrahim has the exclusive rights to market Ondansetron Rapidfilm® in Turkey.
- An increase in the diagnosed prevalent population will drive growth of nearly $4.3 billion in the Chronic Obstructive Pulmonary Disease market
- FDA has approved Cambia™, Potassium Diclofenac Powder for Oral Solution for the treatment of acute migraine attacks with or without aura, originally developed by APR Applied Pharma Research SA (APR)
- More news...
PR Newswire
- Long-term Investment Secured - Swiss Foundation Supports Innovative Concept for Patients With Diabetes
- ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
- Marie Curie Tops Poll of the Most Inspirational Women in Science
- More news...
© Copyright 1995-2009 Pharmalicensing, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us